MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726

MetaVia Inc.

2026-Q1 EPS reported -$0.79

Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.
Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.
First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.
January 2026 public offering raised ~$9.3M gross proceeds to fund operations.
R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MetaVia Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the first quarter ended March 31, 2026

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-061148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.